Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nuoyan Zhu has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Liangliang Cai

    Department of Basic Medical Immunology, Medical College, Yangzhou University, Yangzhou 225009, China

    2 shared publications
  • Jiahui Wang

    School of Basic Medical Sciences and School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225000, China

    1 shared publication
  • Li Qian

    Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation (Yangzhou University), Faculty of Medicine, Yangzhou University, Yangzhou, Jiangsu, 225001, PR China

    1 shared publication

Latest Publications

  • Open Access

    LYZ Gene as a Novel Therapeutic Target and Diagnostic Biomarker in Glioblastoma: Insights from Multi-Omics Analysis and Functional Validation

    by Nuoyan Zhu, Jiahui Wang, Liangliang Cai

    Immune checkpoint blockade is one of the current treatments for glioblastoma (GBM), which is still a very aggressive and treatment-resistant tumor of the central nervous system. This study focused on the LYZ gene to find new therapeutic targets. We performed a thorough screening of differential gene expressions between GBM and normal samples using many databases (TCGA, GTEx, GEO, and CGGA). Because LYZ is significantly upregulated in GBM tissues and is associated with shorter patient survival periods, we identified it as a gene of interest. LYZ’s position on the exterior side of the plasma membrane and its participation in leukocyte-mediated immunity were identified by functional enrichment analysis, indicating a role in cell surface immune responses. Significant associations between LYZ expression and particular immune cell types were found using immune infiltration analysis, suggesting that LYZ may have an impact on the tumor microenvironment. Within GBM, single-cell research verified LYZ expression in macrophages and monocytes. LYZ was shown to express differently in GBM cell lines than in normal glial cells, according to cellular experimental verification. The LYZ gene’s functional importance in the pathophysiology of GBM was highlighted by the dramatic reduction in cell proliferation, motility, and invasion that resulted from its knockout. These results suggest that LYZ is a viable therapeutic target and possible GBM diagnostic biomarker, which calls for more research into its mechanisms of action and potential clinical use.


  • Open Access

    Upregulation of GZMK, TREM2, and OR4D10 as Prognostic Biomarkers in Thyroid Cancer: A Pan-Cancer and TCGA Data Analysis

    by Nuoyan Zhu, Liangliang Cai, Li Qian

    The study of gene anomalies linked to thyroid cancer is gaining more and more attention, and these molecular indicators can offer scholarly support for thyroid cancer diagnosis, therapy selection, and prognosis. Genotype–tissue expression pan-cancer data and The Cancer Genome Atlas (TCGA) were used to investigate the expression of GZMK, TREM2, and OR4D10. In order to assess the relationship between GZMK, TREM2, and OR4D10 expression and patient outcome, TCGA clinical survival data were used. We used the clusterProfiler R software tool to conduct enrichment analysis of GZMK, TREM2, and OR4D10. Moreover, TCGA database analysis was used to assess the relationship between immune cell infiltration and GZMK, TREM2, and OR4D10 expression. GZMK, TREM2, and OR4D10 were strongly expressed in several kinds of malignancies including thyroid cancer. Gene sets related to proliferation that are involved in leukocyte cell–cell adhesion and mononuclear cell differentiation were significantly correlated with high expression of GZMK, TREM2, and OR4D10. Additional investigation revealed a correlation between high T cell and DC (dendritic cell) infiltration scores and high expression of GZMK, TREM2, and OR4D10. According to our research, OR4D10, TREM2, and GZMK could all be genes associated with thyroid cancer.